-
1
-
-
78049485263
-
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
-
Ferlay, J. et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127, 2893-2917 (2010).
-
(2010)
Int. J. Cancer
, vol.127
, pp. 2893-2917
-
-
Ferlay, J.1
-
2
-
-
19644381818
-
Hepatocellular carcinoma: The need for progress
-
DOI 10.1200/JCO.2005.03.196
-
Thomas, M. B. & Zhu, A. X. Hepatocellular carcinoma: the need for progress. J. Clin. Oncol. 23, 2892-2899, (2005). (Pubitemid 46224106)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.13
, pp. 2892-2899
-
-
Thomas, M.B.1
Zhu, A.X.2
-
3
-
-
0003120252
-
-
eds DeVita, V. T., Hellman, S. & Rosenberg, S. A.), (Lippincott Williams and Wilkins, Philadelphia, PA, USA
-
Fong, Y., Kemeny, N. & Lawrence, T. S. in Cancer, Principles and Practice of Oncology 6th edn (eds DeVita, V. T., Hellman, S. & Rosenberg, S. A.) 1162-1203 (Lippincott Williams and Wilkins, Philadelphia, PA, USA, 2001).
-
(2001)
Cancer, Principles and Practice of Oncology 6th Edn
, pp. 1162-1203
-
-
Fong, Y.1
Kemeny, N.2
Lawrence, T.S.3
-
4
-
-
33947732977
-
Angiogenesis: An organizing principle for drug discovery?
-
DOI 10.1038/nrd2115, PII NRD2115
-
Folkman, J. Angiogenesis: an organizing principle for drug discovery? Nat. Rev. Drug Discov. 6, 273-286 (2007). (Pubitemid 46505878)
-
(2007)
Nature Reviews Drug Discovery
, vol.6
, Issue.4
, pp. 273-286
-
-
Folkman, J.1
-
5
-
-
77950960449
-
Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease
-
Van de Veire, S. et al. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell 141, 178-190 (2010).
-
(2010)
Cell
, vol.141
, pp. 178-190
-
-
Van De Veire, S.1
-
6
-
-
47949116252
-
Sorafenib in advanced hepatocellular carcinoma
-
Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378-390 (2008).
-
(2008)
N. Engl. J. Med.
, vol.359
, pp. 378-390
-
-
Llovet, J.M.1
-
7
-
-
2542561964
-
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
-
DOI 10.1056/NEJMoa032691
-
Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342 (2004). (Pubitemid 38702844)
-
(2004)
New England Journal of Medicine
, vol.350
, Issue.23
, pp. 2335-2342
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Novotny, W.3
Cartwright, T.4
Hainsworth, J.5
Heim, W.6
Berlin, J.7
Baron, A.8
Griffing, S.9
Holmgren, E.10
Ferrara, N.11
Fyfe, G.12
Rogers, B.13
Ross, R.14
Kabbinavar, F.15
-
8
-
-
3042761526
-
Angiogenesis in hepatocellular carcinoma: The retrospectives and perspectives
-
Sun, H. C. & Tang, Z. Y. Angiogenesis in hepatocellular carcinoma: the retrospectives and perspectives. J. Cancer Res. Clin. Oncol. 130, 307-319 (2004).
-
(2004)
J. Cancer Res. Clin. Oncol.
, vol.130
, pp. 307-319
-
-
Sun, H.C.1
Tang, Z.Y.2
-
9
-
-
11844254414
-
Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
-
DOI 10.1126/science.1104819
-
Jain, R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58-62 (2005). (Pubitemid 40093472)
-
(2005)
Science
, vol.307
, Issue.5706
, pp. 58-62
-
-
Jain, R.K.1
-
10
-
-
38749084161
-
Taming vessels to treat cancer
-
Jain, R. K. Taming vessels to treat cancer. Sci. Am. 298, 56-63 (2008). (Pubitemid 351182556)
-
(2008)
Scientific American
, vol.298
, Issue.1
, pp. 56-63
-
-
Jain, R.K.1
-
11
-
-
40649109728
-
The wolf in sheep's clothing: The role of interleukin-6 in immunity, inflammation and cancer
-
Naugler, W. E. & Karin, M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol. Med. 14, 109-119 (2008).
-
(2008)
Trends Mol. Med.
, vol.14
, pp. 109-119
-
-
Naugler, W.E.1
Karin, M.2
-
12
-
-
67649946279
-
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: A phase II study
-
Zhu, A. X. et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J. Clin. Oncol. 27, 3027-3035 (2009).
-
(2009)
J. Clin. Oncol.
, vol.27
, pp. 3027-3035
-
-
Zhu, A.X.1
-
13
-
-
33749017926
-
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma
-
DOI 10.1200/JCO.2005.01.3441
-
Abou-Alfa, G. K. et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 24, 4293-4300 (2006). (Pubitemid 46630787)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.26
, pp. 4293-4300
-
-
Abou-Alfa, G.K.1
Schwartz, L.2
Ricci, S.3
Amadori, D.4
Santoro, A.5
Figer, A.6
De Greve, J.7
Douillard, J.-Y.8
Lathia, C.9
Schwartz, B.10
Taylor, I.11
Moscovici, M.12
Saltz, L.B.13
-
14
-
-
45849135992
-
Vascular changes in hepatocellular carcinoma
-
Yang, Z. F. & Poon, R. T. Vascular changes in hepatocellular carcinoma. Anat. Rec. (Hoboken) 291, 721-734 (2008).
-
(2008)
Anat. Rec. (Hoboken)
, vol.291
, pp. 721-734
-
-
Yang, Z.F.1
Poon, R.T.2
-
15
-
-
0030884164
-
Effect of host microenvironment on the microcirculation of human colon adenocarcinoma
-
Fukumura, D., Yuan, F., Monsky, W. L., Chen, Y. & Jain, R. K. Effect of host microenvironment on the microcirculation of human colon adenocarcinoma. Am. J. Pathol. 151, 679-688 (1997). (Pubitemid 27385599)
-
(1997)
American Journal of Pathology
, vol.151
, Issue.3
, pp. 679-688
-
-
Fukumura, D.1
Yuan, F.2
Monsky, W.L.3
Chen, Y.4
Jain, R.K.5
-
16
-
-
34547690632
-
Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinoma
-
DOI 10.1111/j.1440-1746.2007.04997.x
-
Wu, X. Z., Xie, G. R. & Chen, D. Hypoxia and hepatocellular carcinoma: the therapeutic target for hepatocellular carcinoma. J. Gastroenterol. Hepatol. 22, 1178-1182 (2007). (Pubitemid 47222667)
-
(2007)
Journal of Gastroenterology and Hepatology
, vol.22
, Issue.8
, pp. 1178-1182
-
-
Wu, X.-Z.1
Xie, G.-R.2
Chen, D.3
-
17
-
-
34047260282
-
Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: Insights from a mathematical model
-
DOI 10.1158/0008-5472.CAN-06-4102
-
Jain, R. K., Tong, R. T. & Munn, L. L. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res. 67, 2729-2735 (2007). (Pubitemid 46548961)
-
(2007)
Cancer Research
, vol.67
, Issue.6
, pp. 2729-2735
-
-
Jain, R.K.1
Tong, R.T.2
Munn, L.L.3
-
18
-
-
0037423321
-
Angiogenesis-independent endothelial protection of liver: Role of VEGFR-1
-
LeCouter, J. et al. Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science 299, 890-893 (2003).
-
(2003)
Science
, vol.299
, pp. 890-893
-
-
Lecouter, J.1
-
19
-
-
74549133965
-
Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development
-
Lichtenberger, B. M. et al. Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development. Cell 140, 268-279 (2010).
-
(2010)
Cell
, vol.140
, pp. 268-279
-
-
Lichtenberger, B.M.1
-
20
-
-
0035881307
-
Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo
-
Fukumura, D. et al. Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res. 61, 6020-6024 (2001). (Pubitemid 32762531)
-
(2001)
Cancer Research
, vol.61
, Issue.16
, pp. 6020-6024
-
-
Fukumura, D.1
Xu, L.2
Chen, Y.3
Gohongi, T.4
Seed, B.5
Jain, R.K.6
-
21
-
-
0034648765
-
Angiogenesis in cancer and other diseases
-
Carmeliet, P. & Jain, R. K. Angiogenesis in cancer and other diseases. Nature 407, 249-257 (2000).
-
(2000)
Nature
, vol.407
, pp. 249-257
-
-
Carmeliet, P.1
Jain, R.K.2
-
22
-
-
0036842215
-
Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy
-
DOI 10.1200/JCO.2002.10.088
-
Dvorak, H. F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 20, 4368-4380 (2002). (Pubitemid 35266299)
-
(2002)
Journal of Clinical Oncology
, vol.20
, Issue.21
, pp. 4368-4380
-
-
Dvorak, H.F.1
-
23
-
-
33745559710
-
The role of nitric oxide in tumour progression
-
DOI 10.1038/nrc1910, PII N1910
-
Fukumura, D., Kashiwagi, S. & Jain, R. K. The role of nitric oxide in tumour progression. Nat. Rev. Cancer 6, 521-534 (2006). (Pubitemid 43980541)
-
(2006)
Nature Reviews Cancer
, vol.6
, Issue.7
, pp. 521-534
-
-
Fukumura, D.1
Kashiwagi, S.2
Jain, R.K.3
-
24
-
-
0032544686
-
Tumor induction of VEGF promoter activity in stromal cells
-
DOI 10.1016/S0092-8674(00)81731-6
-
Fukumura, D. et al. Tumor induction of VEGF promoter activity in stromal cells. Cell 94, 715-725 (1998). (Pubitemid 28436004)
-
(1998)
Cell
, vol.94
, Issue.6
, pp. 715-725
-
-
Fukumura, D.1
Xavier, R.2
Sugiura, T.3
Chen, Y.4
Park, E.-C.5
Lu, N.6
Selig, M.7
Nielsen, G.8
Taksir, T.9
Jain, R.K.10
Seed, B.11
-
25
-
-
0000391746
-
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
-
Bergers, G. et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2, 737-744 (2000).
-
(2000)
Nat. Cell Biol.
, vol.2
, pp. 737-744
-
-
Bergers, G.1
-
26
-
-
35848951863
-
Angiogenesis in chronic liver disease
-
Amarapurkar, A. D., Amarapurkar, D. N., Vibhav, S. & Patel, N. D. Angiogenesis in chronic liver disease. Ann. Hepatol. 6, 170-173 (2007). (Pubitemid 350277195)
-
(2007)
Annals of Hepatology
, vol.6
, Issue.3
, pp. 170-173
-
-
Amarapurkar, A.D.1
Amarapurkar, D.N.2
Vibhav, S.3
Patel, N.D.4
-
27
-
-
33750621103
-
Significance of circulating endothelial progenitor cells in hepatocellular carcinoma
-
DOI 10.1002/hep.21353
-
Ho, J. W. et al. Significance of circulating endothelial progenitor cells in hepatocellular carcinoma. Hepatology 44, 836-843 (2006). (Pubitemid 46489546)
-
(2006)
Hepatology
, vol.44
, Issue.4
, pp. 836-843
-
-
Ho, J.W.Y.1
Pang, R.W.C.2
Lau, C.3
Sun, C.K.4
Wan, C.Y.5
Sheung, T.F.6
Poon, R.T.P.7
-
28
-
-
0038376002
-
Molecular regulation of vessel maturation
-
DOI 10.1038/nm0603-685
-
Jain, R. K. Molecular regulation of vessel maturation. Nat. Med. 9, 685-693 (2003). (Pubitemid 36749217)
-
(2003)
Nature Medicine
, vol.9
, Issue.6
, pp. 685-693
-
-
Jain, R.K.1
-
29
-
-
0037699954
-
The biology of VEGF and its receptors
-
DOI 10.1038/nm0603-669
-
Ferrara, N., Gerber, H. P. & LeCouter, J. The biology of VEGF and its receptors. Nat. Med. 9, 669-676 (2003). (Pubitemid 36749215)
-
(2003)
Nature Medicine
, vol.9
, Issue.6
, pp. 669-676
-
-
Ferrara, N.1
Gerber, H.-P.2
LeCouter, J.3
-
30
-
-
7244250405
-
Angiogenesis and hepatocellular carcinoma
-
DOI 10.1016/j.jhep.2004.09.006, PII S0168827804003940
-
Semela, D. & Dufour, J. F. Angiogenesis and hepatocellular carcinoma. J. Hepatol. 41, 864-880 (2004). (Pubitemid 39434320)
-
(2004)
Journal of Hepatology
, vol.41
, Issue.5
, pp. 864-880
-
-
Semela, D.1
Dufour, J.-F.2
-
31
-
-
33748653168
-
Emerging drugs for hepatocellular carcinoma
-
DOI 10.1517/14728214.11.3.469
-
Roberts, L. R. & Gores, G. J. Emerging drugs for hepatocellular carcinoma. Expert Opin. Emerg. Drugs 11, 469-487 (2006). (Pubitemid 44386371)
-
(2006)
Expert Opinion on Emerging Drugs
, vol.11
, Issue.3
, pp. 469-487
-
-
Roberts, L.R.1
Gores, G.J.2
-
32
-
-
38449116573
-
Angiogenesis soluble factors as hepatocellular carcinoma noninvasive markers for monitoring hepatitis C virus cirrhotic patients awaiting liver transplantation
-
DOI 10.1097/01.tp.0000287596.91520.1a, PII 0000789020071127000008
-
Mas, V. R., Maluf, D. G., Archer, K. J., Yanek, K. C. & Fisher, R. A. Angiogenesis soluble factors as hepatocellular carcinoma noninvasive markers for monitoring hepatitis C virus cirrhotic patients awaiting liver transplantation. Transplantation 84, 1262-1271 (2007). (Pubitemid 351339314)
-
(2007)
Transplantation
, vol.84
, Issue.10
, pp. 1262-1271
-
-
Mas, V.R.1
Maluf, D.G.2
Archer, K.J.3
Yanek, K.C.4
Fisher, R.A.5
-
33
-
-
0034802560
-
Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma
-
DOI 10.1016/S0002-9610(01)00708-5, PII S0002961001007085
-
Poon, R. T. et al. Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma. Am. J. Surg. 182, 298-304 (2001). (Pubitemid 32918381)
-
(2001)
American Journal of Surgery
, vol.182
, Issue.3
, pp. 298-304
-
-
Poon, R.T.-P.1
Ng, I.O.-L.2
Lau, C.3
Yu, W.-C.4
Fan, S.-T.5
Wong, J.6
-
34
-
-
0035132143
-
Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: A prospective study
-
DOI 10.1097/00000658-200102000-00012
-
Poon, R. T. et al. Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann. Surg. 233, 227-235 (2001). (Pubitemid 32106077)
-
(2001)
Annals of Surgery
, vol.233
, Issue.2
, pp. 227-235
-
-
Poon, R.T.-P.1
Ng, I.O.-L.2
Lau, C.3
Zhu, L.-X.4
Yu, W.-C.5
Lo, C.-M.6
Fan, S.-T.7
Wong, J.8
-
35
-
-
0036254553
-
Requisite role of VEGF receptors in angiogenesis of hepatocellular carcinoma: A comparison with angiopoietin/Tie pathway
-
Dhar, D. K. et al. Requisite role of VEGF receptors in angiogenesis of hepatocellular carcinoma: a comparison with angiopoietin/Tie pathway. Anticancer Res. 22, 379-386 (2002). (Pubitemid 34475326)
-
(2002)
Anticancer Research
, vol.22
, Issue.1 A
, pp. 379-386
-
-
Dhar, D.K.1
Naora, H.2
Yamanoi, A.3
Ono, T.4
Kohno, H.5
Otani, H.6
Nagasue, N.7
-
36
-
-
0031778206
-
Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: Possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver
-
DOI 10.1002/hep.510270613
-
El-Assal, O. N. et al. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology 27, 1554-1562 (1998). (Pubitemid 28264678)
-
(1998)
Hepatology
, vol.27
, Issue.6
, pp. 1554-1562
-
-
El-Assal, O.N.1
Yamanoi, A.2
Soda, Y.3
Yamaguchi, M.4
Igarashi, M.5
Yamamoto, A.6
Nabika, T.7
Nagasue, N.8
-
37
-
-
0004623809
-
Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis
-
Park, Y. N., Kim, Y. B., Yang, K. M. & Park, C. Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis. Arch. Pathol. Lab. Med. 124, 1061-1065 (2000). (Pubitemid 30602050)
-
(2000)
Archives of Pathology and Laboratory Medicine
, vol.124
, Issue.7
, pp. 1061-1065
-
-
Park, Y.N.1
Kim, Y.-B.2
Yang, K.M.3
Park, C.4
-
38
-
-
0031807538
-
Expression of vascular endothelial growth factor in human hepatocellular carcinoma
-
DOI 10.1002/hep.510280111
-
Yamaguchi, R. et al. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 28, 68-77 (1998). (Pubitemid 28299987)
-
(1998)
Hepatology
, vol.28
, Issue.1
, pp. 68-77
-
-
Yamaguchi, R.1
Yano, H.2
Iemura, A.3
Ogasawara, S.4
Haramaki, M.5
Kojiro, M.6
-
39
-
-
0031955570
-
Significance of vascular endothelial growth factor mRNA expression in invasion and metastasis of hepatocellular carcinoma
-
Li, X. M., Tang, Z. Y., Zhou, G., Lui, Y. K. & Ye, S. L. Significance of vascular endothelial growth factor mRNA expression in invasion and metastasis of hepatocellular carcinoma. J. Exp. Clin. Cancer Res. 17, 13-17 (1998). (Pubitemid 28215959)
-
(1998)
Journal of Experimental and Clinical Cancer Research
, vol.17
, Issue.1
, pp. 13-17
-
-
Li, X.M.1
Tang, Z.Y.2
Zhou, G.3
Lui, Y.K.4
Ye, S.L.5
-
40
-
-
20344371480
-
Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma
-
Yao, D. F. et al. Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma. Hepatobiliary Pancreat. Dis. Int. 4, 220-226 (2005).
-
(2005)
Hepatobiliary Pancreat. Dis. Int.
, vol.4
, pp. 220-226
-
-
Yao, D.F.1
-
41
-
-
0033986802
-
Expression of platelet-derived endothelial cell growth factor and vascular endothelial growth factor in hepatocellular carcinoma and portal vein tumor thrombus
-
Zhou, J. et al. Expression of platelet-derived endothelial cell growth factor and vascular endothelial growth factor in hepatocellular carcinoma and portal vein tumor thrombus. J. Cancer Res. Clin. Oncol. 126, 57-61 (2000). (Pubitemid 30006353)
-
(2000)
Journal of Cancer Research and Clinical Oncology
, vol.126
, Issue.1
, pp. 57-61
-
-
Zhou, J.1
Tang, Z.-Y.2
Fan, J.3
Wu, Z.-Q.4
Li, X.-M.5
Liu, Y.-K.6
Liu, F.7
Sun, H.-C.8
Ye, S.-L.9
-
42
-
-
4944234987
-
Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma
-
DOI 10.1002/bjs.4594
-
Poon, R. T. et al. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br. J. Surg. 91, 1354-1360 (2004). (Pubitemid 39331462)
-
(2004)
British Journal of Surgery
, vol.91
, Issue.10
, pp. 1354-1360
-
-
Poon, R.T.P.1
Ho, J.W.Y.2
Tong, C.S.W.3
Lau, C.4
Ng, I.O.L.5
Fan, S.-T.6
-
43
-
-
0043163428
-
Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery
-
DOI 10.1245/ASO.2003.10.002
-
Chao, Y. et al. Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann. Surg. Oncol. 10, 355-362 (2003). (Pubitemid 40486931)
-
(2003)
Annals of Surgical Oncology
, vol.10
, Issue.4
, pp. 355-362
-
-
Chao, Y.1
Li, C.-P.2
Chau, G.-Y.3
Chen, C.-P.4
King, K.-L.5
Lui, W.-Y.6
Yen, S.-H.7
Chang, F.-Y.8
Chan, W.-K.9
Lee, S.-D.10
-
44
-
-
70350506052
-
High serum levels of vascular endothelial growth factor after hepatectomy are associated with poor prognosis in hepatocellular carcinoma
-
Tamesa, T. et al. High serum levels of vascular endothelial growth factor after hepatectomy are associated with poor prognosis in hepatocellular carcinoma. Hepatogastroenterology 56, 1122-1126 (2009).
-
(2009)
Hepatogastroenterology
, vol.56
, pp. 1122-1126
-
-
Tamesa, T.1
-
45
-
-
10244266374
-
A phase I surrogate endpoint study of SU6668 in patients with solid tumors
-
DOI 10.1023/B:DRUG.0000036688.96453.8d
-
Xiong, H. Q. et al. A phase I surrogate endpoint study of SU6668 in patients with solid tumors. Invest. New Drugs 22, 459-466 (2004). (Pubitemid 39619822)
-
(2004)
Investigational New Drugs
, vol.22
, Issue.4
, pp. 459-466
-
-
Xiong, H.Q.1
Herbst, R.2
Faria, S.C.3
Scholz, C.4
Davis, D.5
Jackson, E.F.6
Madden, T.7
McConkey, D.8
Hicks, M.9
Hess, K.10
Charnsangavej, C.11
Abbruzzese, J.L.12
-
46
-
-
4644289324
-
Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level
-
Li, X., Feng, G. S., Zheng, C. S., Zhuo, C. K. & Liu, X. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J. Gastroenterol. 10, 2878-2882 (2004). (Pubitemid 39303010)
-
(2004)
World Journal of Gastroenterology
, vol.10
, Issue.19
, pp. 2878-2882
-
-
Li, X.1
Feng, G.-S.2
Zheng, C.-S.3
Zhuo, C.-K.4
Liu, X.5
-
47
-
-
54949109005
-
Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients
-
Shim, J. H. et al. Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Cancer Sci. 99, 2037-2044 (2008).
-
(2008)
Cancer Sci.
, vol.99
, pp. 2037-2044
-
-
Shim, J.H.1
-
48
-
-
41949113329
-
TTranscatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): The role of angiogenesis and invasiveness
-
DOI 10.1111/j.1572-0241.2007.01712.x
-
Sergio, A. et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am. J. Gastroenterol. 103, 914-921 (2008). (Pubitemid 351506379)
-
(2008)
American Journal of Gastroenterology
, vol.103
, Issue.4
, pp. 914-921
-
-
Sergio, A.1
Cristofori, C.2
Cardin, R.3
Pivetta, G.4
Ragazzi, R.5
Baldan, A.6
Girardi, L.7
Cillo, U.8
Burra, P.9
Giacomin, A.10
Farinati, F.11
-
49
-
-
34249900712
-
High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: Importance of tumor biomarker in ablative therapies
-
DOI 10.1245/s10434-007-9366-z
-
Poon, R. T. et al. High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies. Ann. Surg. Oncol. 14, 1835-1845 (2007). (Pubitemid 46870942)
-
(2007)
Annals of Surgical Oncology
, vol.14
, Issue.6
, pp. 1835-1845
-
-
Poon, R.T.P.1
Lau, C.2
Pang, R.3
Ng, K.K.4
Yuen, J.5
Fan, S.T.6
-
50
-
-
4444366693
-
Effect of c-myc, Ki-67, MMP-2 and VEGF expression on prognosis of hepatocellular carcinoma patients undergoing tumor resection
-
Cui, J., Dong, B. W., Liang, P., Yu, X. L. & Yu, D. J. Effect of c-myc, Ki-67, MMP-2 and VEGF expression on prognosis of hepatocellular carcinoma patients undergoing tumor resection. World J. Gastroenterol. 10, 1533-1536 (2004). (Pubitemid 39206824)
-
(2004)
World Journal of Gastroenterology
, vol.10
, Issue.10
, pp. 1533-1536
-
-
Cui, J.1
Dong, B.-W.2
Liang, P.3
Yu, X.-L.4
Yu, D.-J.5
-
51
-
-
69049116144
-
High expressions of vascular endothelial growth factor and platelet-derived endothelial cell growth factor predict poor prognosis in alpha-fetoprotein-negative hepatocellular carcinoma patients after curative resection
-
Hu, J. et al. High expressions of vascular endothelial growth factor and platelet-derived endothelial cell growth factor predict poor prognosis in alpha-fetoprotein-negative hepatocellular carcinoma patients after curative resection. J. Cancer Res. Clin. Oncol. 135, 1359-1367 (2009).
-
(2009)
J. Cancer Res. Clin. Oncol.
, vol.135
, pp. 1359-1367
-
-
Hu, J.1
-
52
-
-
58149329048
-
Expression of vascular endothelial growth factor (VEGF) family members and prognosis after hepatic resection in HBV-related hepatocellular carcinoma [Korean]
-
Moon, J. I. et al. Expression of vascular endothelial growth factor (VEGF) family members and prognosis after hepatic resection in HBV-related hepatocellular carcinoma [Korean]. Korean J. Hepatol. 14, 185-196 (2008).
-
(2008)
Korean J. Hepatol.
, vol.14
, pp. 185-196
-
-
Moon, J.I.1
-
53
-
-
1542685212
-
Prognostic significance of preoperative circulating vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma: A prospective study
-
Jeng, K. S. et al. Prognostic significance of preoperative circulating vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma: a prospective study. World J. Gastroenterol. 10, 643-648 (2004).
-
(2004)
World J. Gastroenterol.
, vol.10
, pp. 643-648
-
-
Jeng, K.S.1
-
54
-
-
1542790444
-
Is the vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma of prognostic value after resection?
-
Jeng, K. S. et al. Is the vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma of prognostic value after resection? World J. Gastroenterol. 10, 676-681 (2004).
-
(2004)
World J. Gastroenterol.
, vol.10
, pp. 676-681
-
-
Jeng, K.S.1
-
55
-
-
34047159945
-
Placenta growth factor not vascular endothelial growth factor A or C can predict the early recurrence after radical resection of hepatocellular carcinoma
-
Ho, M. C. et al. Placenta growth factor not vascular endothelial growth factor A or C can predict the early recurrence after radical resection of hepatocellular carcinoma. Cancer Lett. 250, 237-249 (2007).
-
(2007)
Cancer Lett.
, vol.250
, pp. 237-249
-
-
Ho, M.C.1
-
56
-
-
33645740560
-
Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma: Importance of angiopoietin-2 and hypoxia-induced factor-1 alpha
-
Wada, H. et al. Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma: importance of angiopoietin-2 and hypoxia-induced factor-1 alpha. Liver Int. 26, 414-423 (2006).
-
(2006)
Liver Int.
, vol.26
, pp. 414-423
-
-
Wada, H.1
-
57
-
-
57749189578
-
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial
-
Cheng, A. L. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10, 25-34 (2009).
-
(2009)
Lancet Oncol.
, vol.10
, pp. 25-34
-
-
Cheng, A.L.1
-
58
-
-
38049097938
-
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling
-
McDermott, U. et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc. Natl Acad. Sci. USA 104, 19936-19941 (2007).
-
(2007)
Proc. Natl Acad. Sci. USA
, vol.104
, pp. 19936-19941
-
-
McDermott, U.1
-
59
-
-
78649972858
-
Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: Results of a phase I study
-
Dufour, J. F. et al. Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. Oncologist 15, 1198-1204 (2010).
-
(2010)
Oncologist
, vol.15
, pp. 1198-1204
-
-
Dufour, J.F.1
-
60
-
-
79551521053
-
Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: Results of NSABP protocol C-08
-
Allegra, C. J. et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J. Clin. Oncol. 29, 11-16 (2010).
-
(2010)
J. Clin. Oncol.
, vol.29
, pp. 11-16
-
-
Allegra, C.J.1
-
61
-
-
79951977298
-
Lessons from the adjuvant bevacizumab trial in colon cancer: What next?
-
Van Cutsem, E., Lambrechts, D., Prenen, H., Jain, R. K. & Carmeliet, P. Lessons from the adjuvant bevacizumab trial in colon cancer: what next? J. Clin. Oncol. 29, 1-4 (2010).
-
(2010)
J. Clin. Oncol.
, vol.29
, pp. 1-4
-
-
Van Cutsem, E.1
Lambrechts, D.2
Prenen, H.3
Jain, R.K.4
Carmeliet, P.5
-
63
-
-
12244301581
-
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship
-
Mendel, D. B. et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9, 327-337 (2003). (Pubitemid 36109749)
-
(2003)
Clinical Cancer Research
, vol.9
, Issue.1 I
, pp. 327-337
-
-
Mendel, D.B.1
Douglas Laird, A.2
Xin, X.3
Louie, S.G.4
Christensen, J.G.5
Li, G.6
Schreck, R.E.7
Abrams, T.J.8
Ngai, T.J.9
Lee, L.B.10
Murray, L.J.11
Carver, J.12
Chan, E.13
Moss, K.G.14
Haznedar, J.O.15
Sukbuntherng, J.16
Blake, R.A.17
Sun, L.18
Tang, C.19
Miller, T.20
Shirazian, S.21
McMahon, G.22
Cherrington, J.M.23
more..
-
64
-
-
0036769119
-
Regulation and targets of receptor tyrosine kinases
-
Pawson, T. Regulation and targets of receptor tyrosine kinases. Eur. J. Cancer 38 (Suppl. 5), S3-S10 (2002).
-
(2002)
Eur. J. Cancer
, vol.38
, Issue.SUPPL. 5
-
-
Pawson, T.1
-
65
-
-
67651165187
-
Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: An open-label, multicentre, phase II study
-
Faivre, S. et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol. 10, 794-800 (2009).
-
(2009)
Lancet Oncol.
, vol.10
, pp. 794-800
-
-
Faivre, S.1
-
66
-
-
58049201181
-
Phase II study of sunitinib malate in adult patients with metastatic or surgically unresectable hepatocellular carcinoma (HCC) [abstract]
-
Hoda, D. et al. Phase II study of sunitinib malate in adult patients with metastatic or surgically unresectable hepatocellular carcinoma (HCC) [abstract]. Proc. 2008 Gastrointestinal Cancers Symp. a267 (2008).
-
(2008)
Proc. 2008 Gastrointestinal Cancers Symp.
, vol.A267
-
-
Hoda, D.1
-
67
-
-
77950546450
-
Continuous sunitinib treatment in patients with advanced hepatocellular carcinoma: A Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06)
-
Koeberle, D. et al. Continuous sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist 15, 285-292 (2010).
-
(2010)
Oncologist
, vol.15
, pp. 285-292
-
-
Koeberle, D.1
-
68
-
-
33749505836
-
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial
-
DOI 10.1016/S0140-6736(06)69446-4, PII S0140673606694464
-
Demetri, G. D. et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368, 1329-1338 (2006). (Pubitemid 44528723)
-
(2006)
Lancet
, vol.368
, Issue.9544
, pp. 1329-1338
-
-
Demetri, G.D.1
Van Oosterom, A.T.2
Garrett, C.R.3
Blackstein, M.E.4
Shah, M.H.5
Verweij, J.6
McArthur, G.7
Judson, I.R.8
Heinrich, M.C.9
Morgan, J.A.10
Desai, J.11
Fletcher, C.D.12
George, S.13
Bello, C.L.14
Huang, X.15
Baum, C.M.16
Casali, P.G.17
-
69
-
-
68949145218
-
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma
-
Motzer, R. J. et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 3584-3590 (2009).
-
(2009)
J. Clin. Oncol.
, vol.27
, pp. 3584-3590
-
-
Motzer, R.J.1
-
70
-
-
60649087564
-
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis
-
Ebos, J. M. et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15, 232-239 (2009).
-
(2009)
Cancer Cell
, vol.15
, pp. 232-239
-
-
Ebos, J.M.1
-
71
-
-
84860254547
-
A phase II study of ramucirumab as first-line monotherapy in patients with advanced hepatocellular carcinoma [abstract]
-
Zhu, A. X. et al. A phase II study of ramucirumab as first-line monotherapy in patients with advanced hepatocellular carcinoma [abstract]. J. Clin. Oncol. 28 (15 Suppl.), a4083 (2010).
-
(2010)
J. Clin. Oncol.
, vol.28
, Issue.15 SUPPL.
-
-
Zhu, A.X.1
-
72
-
-
0034796595
-
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
-
DOI 10.1038/nm0901-987
-
Jain, R. K. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat. Med. 7, 987-989 (2001). (Pubitemid 32937367)
-
(2001)
Nature Medicine
, vol.7
, Issue.9
, pp. 987-989
-
-
Jain, R.K.1
-
73
-
-
11144354392
-
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
-
DOI 10.1038/nm988
-
Willett, C. G. et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 10, 145-147 (2004). (Pubitemid 38524883)
-
(2004)
Nature Medicine
, vol.10
, Issue.2
, pp. 145-147
-
-
Willett, C.G.1
Boucher, Y.2
Di Tomaso, E.3
Duda, D.G.4
Munn, L.L.5
Tong, R.T.6
Chung, D.C.7
Sahani, D.V.8
Kalva, S.P.9
Kozin, S.V.10
Mino, M.11
Cohen, K.S.12
Scadden, D.T.13
Hartford, A.C.14
Fischman, A.J.15
Clark, J.W.16
Ryan, D.P.17
Zhu, A.X.18
Blaszkowsky, L.S.19
Chen, H.X.20
Shellito, P.C.21
Lauwers, G.Y.22
Jain, R.K.23
more..
-
74
-
-
46449091500
-
Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma
-
Siegel, A. B. et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J. Clin. Oncol. 26, 2992-2998 (2008).
-
(2008)
J. Clin. Oncol.
, vol.26
, pp. 2992-2998
-
-
Siegel, A.B.1
-
75
-
-
33646351795
-
Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma
-
DOI 10.1200/JCO.2005.04.9130
-
Zhu, A. X. et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 24, 1898-1903 (2006). (Pubitemid 46638989)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.12
, pp. 1898-1903
-
-
Zhu, A.X.1
Blaszkowsky, L.S.2
Ryan, D.P.3
Clark, J.W.4
Muzikansky, A.5
Horgan, K.6
Sheehan, S.7
Hale, K.E.8
Enzinger, P.C.9
Bhargava, P.10
Stuart, K.11
-
76
-
-
84984578313
-
Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma
-
Hsu, C. H. et al. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br. J. Cancer 102, 981-986 (2010).
-
(2010)
Br. J. Cancer
, vol.102
, pp. 981-986
-
-
Hsu, C.H.1
-
77
-
-
36549089272
-
Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma: A phase II study [abstract]
-
Sun, W. et al. Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma: a phase II study [abstract]. J. Clin. Oncol. 25 (18 Suppl.), a4574 (2007).
-
(2007)
J. Clin. Oncol.
, vol.25
, Issue.18 SUPPL.
-
-
Sun, W.1
-
78
-
-
38049092474
-
Bevacizumab in patients with advanced hepatocellular carcinoma: Preliminary results of a phase II study with circulating endothelial cell monitoring [abstract]
-
Malka, D. et al. Bevacizumab in patients with advanced hepatocellular carcinoma: preliminary results of a phase II study with circulating endothelial cell monitoring [abstract]. J. Clin. Oncol. 25 (18 Suppl.), a4570 (2007).
-
(2007)
J. Clin. Oncol.
, vol.25
, Issue.18 SUPPL.
-
-
Malka, D.1
-
79
-
-
60849124241
-
Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma
-
Thomas, M. B. et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J. Clin. Oncol. 27, 843-850 (2009).
-
(2009)
J. Clin. Oncol.
, vol.27
, pp. 843-850
-
-
Thomas, M.B.1
-
80
-
-
33646586669
-
Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor
-
DOI 10.1158/1535-7163.MCT-05-0410
-
Albert, D. H. et al. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol. Cancer Ther. 5, 995-1006 (2006). (Pubitemid 43724600)
-
(2006)
Molecular Cancer Therapeutics
, vol.5
, Issue.4
, pp. 995-1006
-
-
Albert, D.H.1
Tapang, P.2
Magoc, T.J.3
Pease, L.J.4
Reuter, D.R.5
Wei, R.-Q.6
Li, J.7
Guo, J.8
Bousquet, P.F.9
Ghoreishi-Haack, N.S.10
Wang, B.11
Bukofzer, G.T.12
Wang, Y.-C.13
Stavropoulos, J.A.14
Hartandi, K.15
Niquette, A.L.16
Soni, N.17
Johnson, E.F.18
McCall, J.O.19
Bouska, J.J.20
Luo, Y.21
Donawho, C.K.22
Dai, Y.23
Marcotte, P.A.24
Glaser, K.B.25
Michaelides, M.R.26
Davidsen, S.K.27
more..
-
81
-
-
78650847886
-
Linifanib phase II trial in patients with advanced hepatocellular carcinoma [abstract]
-
Toh, H. et al. Linifanib phase II trial in patients with advanced hepatocellular carcinoma [abstract]. J. Clin. Oncol. 28 (15 Suppl.), a4038 (2010).
-
(2010)
J. Clin. Oncol.
, vol.28
, Issue.15 SUPPL.
-
-
Toh, H.1
-
82
-
-
20144370978
-
AZD2171: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer
-
DOI 10.1158/0008-5472.CAN-04-4409
-
Wedge, S. R. et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 65, 4389-4400 (2005). (Pubitemid 40775678)
-
(2005)
Cancer Research
, vol.65
, Issue.10
, pp. 4389-4400
-
-
Wedge, S.R.1
Kendrew, J.2
Hennequin, L.F.3
Valentine, P.J.4
Barry, S.T.5
Brave, S.R.6
Smith, N.R.7
James, N.H.8
Dukes, M.9
Curwen, J.O.10
Chester, R.11
Jackson, J.A.12
Boffey, S.J.13
Kilburn, L.L.14
Barnett, S.15
Richmond, G.H.P.16
Wadsworth, P.F.17
Walker, M.18
Bigley, A.L.19
Taylor, S.T.20
Cooper, L.21
Beck, S.22
Jurgensmeier, J.M.23
Ogilvie, D.J.24
more..
-
83
-
-
38049030409
-
NCCTG phase II trial (N044J) of AZD2171 for patients with hepatocellular carcinoma-interim review of toxicity [abstract]
-
Alberts, S. R. et al. NCCTG phase II trial (N044J) of AZD2171 for patients with hepatocellular carcinoma-interim review of toxicity [abstract]. Proc. 2007 Gastrointestinal Cancers Symp. a186 (2007).
-
(2007)
Proc. 2007 Gastrointestinal Cancers Symp.
-
-
Alberts, S.R.1
-
84
-
-
71449116258
-
A phase I study of pazopanib in patients with advanced hepatocellular carcinoma [abstract]
-
Yau, C. C. et al. A phase I study of pazopanib in patients with advanced hepatocellular carcinoma [abstract]. J. Clin. Oncol. 27 (15 Suppl.), a3561 (2009).
-
(2009)
J. Clin. Oncol.
, vol.27
, Issue.15 SUPPL.
-
-
Yau, C.C.1
-
85
-
-
0034655182
-
PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration
-
Wood, J. M. et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 60, 2178-89 (2000). (Pubitemid 30225181)
-
(2000)
Cancer Research
, vol.60
, Issue.8
, pp. 2178-2189
-
-
Wood, J.M.1
Bold, G.2
Buchdunger, E.3
Cozens, R.4
Ferrari, S.5
Frei, J.6
Hofmann, F.7
Mestan, J.8
Mett, H.9
O'Reilly, T.10
Persohn, E.11
Rosel, J.12
Schnell, C.13
Stover, D.14
Theuer, A.15
Towbin, H.16
Wenger, F.17
Woods-Cook, K.18
Menrad, A.19
Siemeister, G.20
Schirner, M.21
Thierauch, K.-H.22
Schneider, M.R.23
Drevs, J.24
Martiny-Baron, G.25
Totzke, F.26
Marme, D.27
more..
-
86
-
-
0037099598
-
PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging
-
Drevs, J. et al. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res. 62, 4015-4022 (2002). (Pubitemid 34791068)
-
(2002)
Cancer Research
, vol.62
, Issue.14
, pp. 4015-4022
-
-
Drevs, J.1
Muller-Driver, R.2
Wittig, C.3
Fuxius, S.4
Esser, N.5
Hugenschmidt, H.6
Konerding, M.A.7
Allegrini, P.R.8
Wood, J.9
Hennig, J.10
Unger, C.11
Marme, D.12
-
87
-
-
39849106728
-
Influence of hepatic dysfunction on safety, tolerability, and pharmacokinetics of PTK787/ZK 222584 in patients with unresectable hepatocellular carcinoma [abstract]
-
Koch, I. et al. Influence of hepatic dysfunction on safety, tolerability, and pharmacokinetics of PTK787/ZK 222584 in patients with unresectable hepatocellular carcinoma [abstract]. J. Clin. Oncol. 23 (16 Suppl.), a4134 (2005).
-
(2005)
J. Clin. Oncol.
, vol.23
, Issue.16 SUPPL.
-
-
Koch, I.1
-
88
-
-
78249288161
-
Phase 1-2 trial of PTK787/ZK222584 combined with intravenous doxorubicin for treatment of patients with advanced hepatocellular carcinoma: Implication for antiangiogenic approach to hepatocellular carcinoma
-
Yau, T. et al. Phase 1-2 trial of PTK787/ZK222584 combined with intravenous doxorubicin for treatment of patients with advanced hepatocellular carcinoma: implication for antiangiogenic approach to hepatocellular carcinoma. Cancer 116, 5022-5029 (2010).
-
(2010)
Cancer
, vol.116
, pp. 5022-5029
-
-
Yau, T.1
-
89
-
-
58149175849
-
Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma
-
Huynh, H. et al. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin. Cancer Res. 14, 6146-6153 (2008).
-
(2008)
Clin. Cancer Res.
, vol.14
, pp. 6146-6153
-
-
Huynh, H.1
-
90
-
-
72949117051
-
TSU68, an antiangiogenic receptor tyrosine kinase inhibitor, induces tumor vascular normalization in a human cancer xenograft nude mouse model
-
Ohta, M. et al. TSU68, an antiangiogenic receptor tyrosine kinase inhibitor, induces tumor vascular normalization in a human cancer xenograft nude mouse model. Surg. Today 39, 1046-1053 (2009).
-
(2009)
Surg. Today
, vol.39
, pp. 1046-1053
-
-
Ohta, M.1
-
91
-
-
74549223962
-
An open-label phase II study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma [abstract]
-
Raoul, J. L. et al. An open-label phase II study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma [abstract]. J. Clin. Oncol. 27 (15 Suppl.), a4577 (2009).
-
(2009)
J. Clin. Oncol.
, vol.27
, Issue.15 SUPPL.
-
-
Raoul, J.L.1
-
92
-
-
79953803472
-
A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma
-
Kanai, F. et al. A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma. Cancer Chemother. Pharmacol. 67, 315-324 (2011).
-
(2011)
Cancer Chemother. Pharmacol.
, vol.67
, pp. 315-324
-
-
Kanai, F.1
-
93
-
-
77954236265
-
A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2
-
Eder, J. P. et al. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin. Cancer Res. 16, 3507-3516 (2010).
-
(2010)
Clin. Cancer Res.
, vol.16
, pp. 3507-3516
-
-
Eder, J.P.1
-
94
-
-
44449085884
-
Design and endpoints of clinical trials in hepatocellular carcinoma
-
Llovet, J. M. et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J. Natl Cancer Inst. 100, 698-711 (2008).
-
(2008)
J. Natl Cancer Inst.
, vol.100
, pp. 698-711
-
-
Llovet, J.M.1
-
95
-
-
69549131042
-
Development of sunitinib in hepatocellular carcinoma: Rationale, early clinical experience and correlative studies
-
Zhu, A. X., Duda, D. G., Sahani, D. V. & Jain, R. K. Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience and correlative studies. Cancer J. 15, 263-268 (2009).
-
(2009)
Cancer J.
, vol.15
, pp. 263-268
-
-
Zhu, A.X.1
Duda, D.G.2
Sahani, D.V.3
Jain, R.K.4
-
96
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
-
Therasse, P. et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92, 205-216 (2000).
-
(2000)
J. Natl. Cancer Inst.
, vol.92
, pp. 205-216
-
-
Therasse, P.1
-
97
-
-
73349110120
-
Sunitinib in hepatocellular carcinoma: Redefining appropriate dosing, schedule, and activity end points
-
Faivre, S. J., Bouattour, M., Dreyer, C. & Raymond, E. Sunitinib in hepatocellular carcinoma: redefining appropriate dosing, schedule, and activity end points. J. Clin. Oncol. 27, e248-e250 (2009).
-
(2009)
J. Clin. Oncol.
, vol.27
-
-
Faivre, S.J.1
Bouattour, M.2
Dreyer, C.3
Raymond, E.4
-
98
-
-
0034856294
-
Clinical management of hepatocellular carcinoma. Conclusions of the barcelona-2000 EASL conference
-
DOI 10.1016/S0168-8278(01)00130-1, PII S0168827801001301
-
Bruix, J. et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J. Hepatol. 35, 421-430 (2001). (Pubitemid 32844200)
-
(2001)
Journal of Hepatology
, vol.35
, Issue.3
, pp. 421-430
-
-
Bruix, J.1
Sherman, M.2
Llovet, J.M.3
Beaugrand, M.4
Lencioni, R.5
Burroughs, A.K.6
Christensen, E.7
Pagliaro, L.8
Colombo, M.9
Rodes, J.10
-
99
-
-
13744253539
-
Imaging angiogenesis: Application and potential for drug development
-
DOI 10.1093/jnci/dji023
-
Miller, J. C., Pien, H. H., Sahani, D., Sorensen, A. G. & Thrall, J. H. Imaging angiogenesis: applications and potential for drug development. J. Natl Cancer Inst. 97, 172-187 (2005). (Pubitemid 40277367)
-
(2005)
Journal of the National Cancer Institute
, vol.97
, Issue.3
, pp. 172-187
-
-
Miller, J.C.1
Pien, H.H.2
Sahani, D.3
Sorensen, A.G.4
Thrall, J.H.5
-
100
-
-
42949161642
-
Radiologic measurements of tumor response to treatment: Practical approaches and limitations
-
Suzuki, C. et al. Radiologic measurements of tumor response to treatment: practical approaches and limitations. Radiographics 28, 329-344 (2008).
-
(2008)
Radiographics
, vol.28
, pp. 329-344
-
-
Suzuki, C.1
-
101
-
-
60049085346
-
Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: Are response evaluation criteria in solid tumors reliable?
-
Forner, A. et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 115, 616-623 (2009).
-
(2009)
Cancer
, vol.115
, pp. 616-623
-
-
Forner, A.1
-
102
-
-
67650380136
-
Biomarkers of response and resistance to antiangiogenic therapy
-
Jain, R. K. et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat. Rev. Clin. Oncol. 6, 327-338 (2009).
-
(2009)
Nat. Rev. Clin. Oncol.
, vol.6
, pp. 327-338
-
-
Jain, R.K.1
-
103
-
-
33747830764
-
Hepatocellular carcinoma pathogenesis: From genes to environment
-
DOI 10.1038/nrc1934, PII NRC1934
-
Farazi, P. A. & DePinho, R. A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer 6, 674-687 (2006). (Pubitemid 44286000)
-
(2006)
Nature Reviews Cancer
, vol.6
, Issue.9
, pp. 674-687
-
-
Farazi, P.A.1
DePinho, R.A.2
-
104
-
-
0036831559
-
Vascular and haematopoietic stem cells: Novel targets for anti-angiogenesis therapy?
-
DOI 10.1038/nrc925
-
Rafii, S., Lyden, D., Benezra, R., Hattori, K. & Heissig, B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat. Rev. Cancer 2, 826-835 (2002). (Pubitemid 37328901)
-
(2002)
Nature Reviews Cancer
, vol.2
, Issue.11
, pp. 826-835
-
-
Rafii, S.1
Lyden, D.2
Benezra, R.3
Hattori, K.4
Heissig, B.5
-
105
-
-
79951818748
-
Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: Kinetics and potential biomarker value
-
Zhu, A. X. et al. Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: Kinetics and potential biomarker value. Clin. Cancer Res. 17, 918-927 (2011).
-
(2011)
Clin. Cancer Res.
, vol.17
, pp. 918-927
-
-
Zhu, A.X.1
-
106
-
-
70449523183
-
Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors
-
Kumar, R. et al. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br. J. Cancer 101, 1717-1723 (2009).
-
(2009)
Br. J. Cancer
, vol.101
, pp. 1717-1723
-
-
Kumar, R.1
-
107
-
-
69249149754
-
A phase II study of ABT-869 in hepatocellular carcinoma (HCC): Interim analysis [abstract]
-
Toh, H., Chen, P. & Carr, B. et al. A phase II study of ABT-869 in hepatocellular carcinoma (HCC): interim analysis [abstract]. J. Clin. Oncol. 27 (15 Suppl.), a4581 (2009).
-
(2009)
J. Clin. Oncol.
, vol.27
, Issue.15 SUPPL.
-
-
Toh, H.1
Chen, P.2
Carr, B.3
-
108
-
-
77957559384
-
Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma
-
Shao, Y. Y. et al. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer 116, 4590-4596 (2010).
-
(2010)
Cancer
, vol.116
, pp. 4590-4596
-
-
Shao, Y.Y.1
-
109
-
-
58049197319
-
Circulating biomarkers of sunitinib in patients with unresectable hepatocellular carcinoma (HCC): Analysis of correlations with outcome and tumor imaging parameters [abstact]
-
DePrimo, S. E. et al. Circulating biomarkers of sunitinib in patients with unresectable hepatocellular carcinoma (HCC): analysis of correlations with outcome and tumor imaging parameters [abstact]. J. Clin. Oncol. 26 (Suppl.), a4593 (2008).
-
(2008)
J. Clin. Oncol.
, vol.26
, Issue.SUPPL.
-
-
Deprimo, S.E.1
-
110
-
-
74549155611
-
Circulating endothelial cells (CECs) and angiogenic proteins monitoring in patients (pts) with advanced hepatocellular carcinoma (HCC) treated with bevacizumab [abstract]
-
Boige, V. et al. Circulating endothelial cells (CECs) and angiogenic proteins monitoring in patients (pts) with advanced hepatocellular carcinoma (HCC) treated with bevacizumab [abstract]. J. Clin. Oncol. 27 (15 Suppl.), a4597 (2009).
-
(2009)
J. Clin. Oncol.
, vol.27
, Issue.15 SUPPL.
-
-
Boige, V.1
-
111
-
-
84886354305
-
Molecular predictors of response to antiangiogenic therapy in HCC: Data from bevacizumab and erlotinib phase II study [abstract]
-
Kaseb, A. O. et al. Molecular predictors of response to antiangiogenic therapy in HCC: Data from bevacizumab and erlotinib phase II study [abstract]. J. Clin. Oncol. 28 (15 Suppl.), a4046 (2010).
-
(2010)
J. Clin. Oncol.
, vol.28
, Issue.15 SUPPL.
-
-
Kaseb, A.O.1
-
112
-
-
79955617020
-
Prognostic values of baseline circulating endothelial progenitor level for advanced hepatocellular carcinoma (HCC) patients under antiangiogenic therapy [abstract]
-
Shao, Y. et al. Prognostic values of baseline circulating endothelial progenitor level for advanced hepatocellular carcinoma (HCC) patients under antiangiogenic therapy [abstract]. J. Clin. Oncol. 28 (15 Suppl.), a4063 (2010).
-
(2010)
J. Clin. Oncol.
, vol.28
, Issue.15 SUPPL.
-
-
Shao, Y.1
-
113
-
-
2442621619
-
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
-
Ferrara, N., Hillan, K. J., Gerber, H. P. & Novotny, W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3, 391-400 (2004). (Pubitemid 38618122)
-
(2004)
Nature Reviews Drug Discovery
, vol.3
, Issue.5
, pp. 391-400
-
-
Ferrara, N.1
Hillan, K.J.2
Gerber, H.-P.3
Novotny, W.4
-
114
-
-
0037189380
-
Tumor regression by targeted gene delivery to the neovasculature
-
DOI 10.1126/science.1070200
-
Hood, J. D. et al. Tumor regression by targeted gene delivery to the neovasculature. Science 296, 2404-2407 (2002). (Pubitemid 34734217)
-
(2002)
Science
, vol.296
, Issue.5577
, pp. 2404-2407
-
-
Hood, J.D.1
Bednarski, M.2
Frausto, R.3
Guccione, S.4
Reisfeld, R.A.5
Xiang, R.6
Cheresh, D.A.7
-
115
-
-
0034646262
-
Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: In vivo expression and antitumor activity
-
DOI 10.1073/pnas.040337597
-
Gagnon, M. L. et al. Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: In vivo expression and antitumor activity. Proc. Natl Acad. Sci. USA 97, 2573-2578 (2000). (Pubitemid 30159212)
-
(2000)
Proceedings of the National Academy of Sciences of the United States of America
, vol.97
, Issue.6
, pp. 2573-2578
-
-
Gagnon, M.L.1
Bielenberg, D.R.2
Gechtman, Z.3
Miao, H.-Q.4
Takashima, S.5
Soker, S.6
Klagsbrun, M.7
-
116
-
-
30744479430
-
Angiogenesis in life, disease and medicine
-
DOI 10.1038/nature04478, PII NATURE04478
-
Carmeliet, P. Angiogenesis in life, disease and medicine. Nature 438, 932-936 (2005). (Pubitemid 43093958)
-
(2005)
Nature
, vol.438
, Issue.7070
, pp. 932-936
-
-
Carmeliet, P.1
-
117
-
-
33847169820
-
Vascular biology: Vessel guidance
-
DOI 10.1038/445722a, PII 445722A
-
Gridley, T. Vascular biology: vessel guidance. Nature 445, 722-723 (2007). (Pubitemid 46279702)
-
(2007)
Nature
, vol.445
, Issue.7129
, pp. 722-723
-
-
Gridley, T.1
-
118
-
-
31544448010
-
Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function
-
DOI 10.1182/blood-2005-03-1000
-
Williams, C. K., Li, J. L., Murga, M., Harris, A. L. & Tosato, G. Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood 107, 931-939 (2006). (Pubitemid 43156289)
-
(2006)
Blood
, vol.107
, Issue.3
, pp. 931-939
-
-
Williams, C.K.1
Li, J.-L.2
Murga, M.3
Harris, A.L.4
Tosato, G.5
-
119
-
-
33847009903
-
Endothelial signalling by the Notch ligand Delta-like 4 restricts angiogenesis
-
DOI 10.1242/dev.003244
-
Leslie, J. D. et al. Endothelial signalling by the Notch ligand Delta-like 4 restricts angiogenesis. Development 134, 839-844 (2007). (Pubitemid 46795675)
-
(2007)
Development
, vol.134
, Issue.5
, pp. 839-844
-
-
Leslie, J.D.1
Ariza-McNaughton, L.2
Bermange, A.L.3
McAdow, R.4
Johnson, S.L.5
Lewis, J.6
-
120
-
-
33845907380
-
Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis
-
DOI 10.1038/nature05313, PII NATURE05313
-
Ridgway, J. et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 444, 1083-1087 (2006). (Pubitemid 46018529)
-
(2006)
Nature
, vol.444
, Issue.7122
, pp. 1083-1087
-
-
Ridgway, J.1
Zhang, G.2
Wu, Y.3
Stawicki, S.4
Liang, W.-C.5
Chanthery, Y.6
Kowalski, J.7
Watts, R.J.8
Callahan, C.9
Kasman, I.10
Singh, M.11
Chien, M.12
Tan, C.13
Hongo, J.-A.S.14
De Sauvage, F.15
Plowman, G.16
Yan, M.17
-
121
-
-
33847046849
-
Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis
-
DOI 10.1038/nature05571, PII NATURE05571
-
Hellstrom, M. et al. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 445, 776-780 (2007). (Pubitemid 46279716)
-
(2007)
Nature
, vol.445
, Issue.7129
, pp. 776-780
-
-
Hellstrom, M.1
Phng, L.-K.2
Hofmann, J.J.3
Wallgard, E.4
Coultas, L.5
Lindblom, P.6
Alva, J.7
Nilsson, A.-K.8
Karlsson, L.9
Gaiano, N.10
Yoon, K.11
Rossant, J.12
Iruela-Arispe, M.L.13
Kalen, M.14
Gerhardt, H.15
Betsholtz, C.16
-
122
-
-
66149133341
-
Angiotensinogen delays angiogenesis and tumor growth of hepatocarcinoma in transgenic mice
-
Vincent, F. et al. Angiotensinogen delays angiogenesis and tumor growth of hepatocarcinoma in transgenic mice. Cancer Res. 69, 2853-2860 (2009).
-
(2009)
Cancer Res.
, vol.69
, pp. 2853-2860
-
-
Vincent, F.1
-
123
-
-
33746800144
-
Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin
-
DOI 10.1016/j.ccr.2006.07.003, PII S1535610806002169
-
Phung, T. L. et al. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell 10, 159-170 (2006). (Pubitemid 44175906)
-
(2006)
Cancer Cell
, vol.10
, Issue.2
, pp. 159-170
-
-
Phung, T.L.1
Ziv, K.2
Dabydeen, D.3
Eyiah-Mensah, G.4
Riveros, M.5
Perruzzi, C.6
Sun, J.7
Monahan-Earley, R.A.8
Shiojima, I.9
Nagy, J.A.10
Lin, M.I.11
Walsh, K.12
Dvorak, A.M.13
Briscoe, D.M.14
Neeman, M.15
Sessa, W.C.16
Dvorak, H.F.17
Benjamin, L.E.18
-
124
-
-
47949096781
-
Cancer-related inflammation
-
Mantovani, A., Allavena, P., Sica, A. & Balkwill, F. Cancer-related inflammation. Nature 454, 436-444 (2008).
-
(2008)
Nature
, vol.454
, pp. 436-444
-
-
Mantovani, A.1
Allavena, P.2
Sica, A.3
Balkwill, F.4
-
125
-
-
4644324186
-
NF-κB functions as a tumour promoter in inflammation-associated cancer
-
DOI 10.1038/nature02924
-
Pikarsky, E. et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431, 461-466 (2004). (Pubitemid 39329586)
-
(2004)
Nature
, vol.431
, Issue.7007
, pp. 461-466
-
-
Pikarsky, E.1
Porat, R.M.2
Stein, I.3
Abramovitch, R.4
Amit, S.5
Kasem, S.6
Gutkovich-Pyest, E.7
Uriell-Shoval, S.8
Galun, E.9
Ben-Neriah, Y.10
-
126
-
-
74549217325
-
Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation
-
He, G. et al. Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell 17, 286-297 (2010).
-
(2010)
Cancer Cell
, vol.17
, pp. 286-297
-
-
He, G.1
-
127
-
-
74549167737
-
Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression
-
Park, E. J. et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140, 197-208 (2010).
-
(2010)
Cell
, vol.140
, pp. 197-208
-
-
Park, E.J.1
-
128
-
-
77954229219
-
Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects
-
Zhang, W. et al. Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin. Cancer Res. 16, 3420-3430 (2010).
-
(2010)
Clin. Cancer Res.
, vol.16
, pp. 3420-3430
-
-
Zhang, W.1
-
129
-
-
48649109203
-
Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis
-
Sakurai, T. et al. Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell 14, 156-165 (2008).
-
(2008)
Cancer Cell
, vol.14
, pp. 156-165
-
-
Sakurai, T.1
-
130
-
-
70449732756
-
The role of macrophage-derived IL-1 in induction and maintenance of angiogenesis
-
Carmi, Y. et al. The role of macrophage-derived IL-1 in induction and maintenance of angiogenesis. J. Immunol. 183, 4705-4714 (2009).
-
(2009)
J. Immunol.
, vol.183
, pp. 4705-4714
-
-
Carmi, Y.1
-
131
-
-
51349098155
-
Cytokines as a key component of cancer-related inflammation
-
Germano, G., Allavena, P. & Mantovani, A. Cytokines as a key component of cancer-related inflammation. Cytokine 43, 374-379 (2008).
-
(2008)
Cytokine
, vol.43
, pp. 374-379
-
-
Germano, G.1
Allavena, P.2
Mantovani, A.3
-
132
-
-
24744438663
-
Induction of interleukin-8 preserves the angiogenic response in HIF-1α-deficient colon cancer cells
-
DOI 10.1038/nm1294
-
Mizukami, Y. et al. Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. Nat. Med. 11, 992-997 (2005). (Pubitemid 41294446)
-
(2005)
Nature Medicine
, vol.11
, Issue.9
, pp. 992-997
-
-
Mizukami, Y.1
Jo, W.-S.2
Duerr, E.-M.3
Gala, M.4
Li, J.5
Zhang, X.6
Zimmer, M.A.7
Iliopoulos, O.8
Zukerberg, L.R.9
Kohgo, Y.10
Lynch, M.P.11
Rueda, B.R.12
Chung, D.C.13
-
133
-
-
25144507526
-
Interleukin 8 in human hepatocellular carcinoma correlates with cancer cell invasion of vessels but not with tumor angiogenesis
-
DOI 10.1245/ASO.2005.07.015
-
Kubo, F. et al. Interleukin 8 in human hepatocellular carcinoma correlates with cancer cell invasion of vessels but not with tumor angiogenesis. Ann. Surg. Oncol. 12, 800-807 (2005). (Pubitemid 41355932)
-
(2005)
Annals of Surgical Oncology
, vol.12
, Issue.10
, pp. 800-807
-
-
Kubo, F.1
Ueno, S.2
Hiwatashi, K.3
Sakoda, M.4
Kawaida, K.5
Nuruki, K.6
Aikou, T.7
-
134
-
-
17844397949
-
The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis
-
DOI 10.1215/S1152851704001061
-
Brat, D. J., Bellail, A. C. & Van Meir, E. G. The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro. Oncol. 7, 122-133 (2005). (Pubitemid 40590513)
-
(2005)
Neuro-Oncology
, vol.7
, Issue.2
, pp. 122-133
-
-
Brat, D.J.1
Bellail, A.C.2
Van Meir, E.G.3
-
135
-
-
38549175201
-
Immunohistochemical expression of stromal cell-derived factor-1 (SDF-1) and CXCR4 ligand receptor system in hepatocellular carcinoma
-
Li, W., Gomez, E. & Zhang, Z. Immunohistochemical expression of stromal cell-derived factor-1 (SDF-1) and CXCR4 ligand receptor system in hepatocellular carcinoma. J. Exp. Clin. Cancer Res. 26, 527-533 (2007). (Pubitemid 351157871)
-
(2007)
Journal of Experimental and Clinical Cancer Research
, vol.26
, Issue.4
, pp. 527-533
-
-
Li, W.1
Gomez, E.2
Zhang, Z.3
-
136
-
-
30344437303
-
VEGF-induced adult neovascularization: Recruitment, retention, and role of accessory cells
-
DOI 10.1016/j.cell.2005.10.036, PII S0092867405012742
-
Grunewald, M. et al. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 124, 175-189 (2006). (Pubitemid 43069318)
-
(2006)
Cell
, vol.124
, Issue.1
, pp. 175-189
-
-
Grunewald, M.1
Avraham, I.2
Dor, Y.3
Bachar-Lustig, E.4
Itin, A.5
Yung, S.6
Chimenti, S.7
Landsman, L.8
Abramovitch, R.9
Keshet, E.10
-
137
-
-
65649140491
-
Expression of stem cell factor and its receptor c-Kit during the development of intrahepatic cholangiocarcinoma
-
Mansuroglu, T. et al. Expression of stem cell factor and its receptor c-Kit during the development of intrahepatic cholangiocarcinoma. Lab. Invest. 89, 562-574 (2009).
-
(2009)
Lab. Invest.
, vol.89
, pp. 562-574
-
-
Mansuroglu, T.1
-
138
-
-
26044455743
-
Correlative study of angiogenesis and dynamic contrast-enhanced magnetic resonance imaging features of hepatocellular carcinoma
-
DOI 10.1080/02841850510021247
-
Wang, B., Gao, Z. Q. & Yan, X. Correlative study of angiogenesis and dynamic contrast-enhanced magnetic resonance imaging features of hepatocellular carcinoma. Acta Radiol. 46, 353-358 (2005). (Pubitemid 41657464)
-
(2005)
Acta Radiologica
, vol.46
, Issue.4
, pp. 353-358
-
-
Wang, B.1
Gao, Z.Q.2
Yan, X.3
-
139
-
-
61749091581
-
Pancreatic endocrine tumors: Tumor blood flow assessed with perfusion CT reflects angiogenesis and correlates with prognostic factors
-
d'Assignies, G. et al. Pancreatic endocrine tumors: tumor blood flow assessed with perfusion CT reflects angiogenesis and correlates with prognostic factors. Radiology 250, 407-416 (2009).
-
(2009)
Radiology
, vol.250
, pp. 407-416
-
-
D'Assignies, G.1
-
140
-
-
34249021801
-
Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue - Initial experience
-
DOI 10.1148/radiol.2433052020
-
Sahani, D. V., Holalkere, N. S., Mueller, P. R. & Zhu, A. X. Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue - initial experience. Radiology 243, 736-743 (2007). (Pubitemid 46799427)
-
(2007)
Radiology
, vol.243
, Issue.3
, pp. 736-743
-
-
Sahani, D.V.1
Holalkere, N.-S.2
Mueller, P.R.3
Zhu, A.X.4
-
141
-
-
40349112983
-
Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma
-
DOI 10.1634/theoncologist.2007-0174
-
Zhu, A. X., Holalkere, N. S., Muzikansky, A., Horgan, K. & Sahani, D. V. Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma. Oncologist 13, 120-125 (2008). (Pubitemid 351342575)
-
(2008)
Oncologist
, vol.13
, Issue.2
, pp. 120-125
-
-
Zhu, A.X.1
Holalkere, N.S.2
Muzikansky, A.3
Horgan, K.4
Sahani, D.V.5
-
142
-
-
79955642250
-
Tumor vascularity assessment in hepatocellular carcinoma and disease free caudate and spleen before and after targeted therapy using a distributed parameter model [abstract]
-
Liaw, J V. et al. Tumor vascularity assessment in hepatocellular carcinoma and disease free caudate and spleen before and after targeted therapy using a distributed parameter model [abstract]. Presented at RSNA 2009.
-
(2009)
RSNA
-
-
Liaw, J.V.1
-
143
-
-
69849103783
-
Regional chemotherapy for unresectable primary liver cancer: Results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival
-
Jarnagin, W. R. et al. Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. Ann. Oncol. 20, 1589-1595 (2009).
-
(2009)
Ann. Oncol.
, vol.20
, pp. 1589-1595
-
-
Jarnagin, W.R.1
-
144
-
-
67650463119
-
A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients
-
Sorensen, A. G. et al. A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res. 69, 5296-5300 (2009).
-
(2009)
Cancer Res.
, vol.69
, pp. 5296-5300
-
-
Sorensen, A.G.1
-
145
-
-
33846149645
-
AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients
-
DOI 10.1016/j.ccr.2006.11.021, PII S1535610806003709
-
Batchelor, T. T. et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11, 83-95 (2007). (Pubitemid 46075199)
-
(2007)
Cancer Cell
, vol.11
, Issue.1
, pp. 83-95
-
-
Batchelor, T.T.1
Sorensen, A.G.2
Di Tomaso, E.3
Zhang, W.-T.4
Duda, DanG.5
Cohen, K.S.6
Kozak, K.R.7
Cahill, D.P.8
Chen, P.-J.9
Zhu, M.10
Ancukiewicz, M.11
Mrugala, M.M.12
Plotkin, S.13
Drappatz, J.14
Louis, D.N.15
Ivy, P.16
Scadden, DavidT.17
Benner, T.18
Loeffler, J.S.19
Wen, P.Y.20
Jain, R.K.21
more..
-
146
-
-
74549143750
-
Sunitinib efficacy in the treatment of metastatic skin adnexal carcinomas: Report of two patients with hidradenocarcinoma and trichoblastic carcinoma
-
Battistella, M. et al. Sunitinib efficacy in the treatment of metastatic skin adnexal carcinomas: report of two patients with hidradenocarcinoma and trichoblastic carcinoma. J. Eur. Acad. Dermatol. Venereol. 24, 199-203 (2010).
-
(2010)
J. Eur. Acad. Dermatol. Venereol.
, vol.24
, pp. 199-203
-
-
Battistella, M.1
-
147
-
-
77952890743
-
Dynamic contrast-enhanced ultrasonography (DCE-US): A new tool for the early evaluation of antiangiogenic treatment
-
Lassau, N. et al. Dynamic contrast-enhanced ultrasonography (DCE-US): a new tool for the early evaluation of antiangiogenic treatment. Target. Oncol. 5, 53-58 (2010).
-
(2010)
Target. Oncol.
, vol.5
, pp. 53-58
-
-
Lassau, N.1
|